To assess how CD8-mIL2 treatment influences tumor antigen–reactive CD8+ T-cell responses at the tumor site, T3 sarcoma tumors were analyzed using MHC tetramers loaded with the immunodominant H-2Kb-restricted mLama4 antigen (39). This evidence concerns the gene CD8A and sarcoma.